CVE-2023-33217 : Vulnerability Insights and Analysis

This article provides detailed insight into CVE-2023-33217, a vulnerability impacting IDEMIA's security products.

Understanding CVE-2023-33217

CVE-2023-33217 involves a design flaw in the firmware upgrade mechanism of certain IDEMIA terminals, leading to a denial of service risk.

What is CVE-2023-33217?

By exploiting the firmware upgrade design flaw, an attacker can cause a permanent denial of service on affected terminals, requiring manufacturer intervention for recovery.

The Impact of CVE-2023-33217

The vulnerability, categorized under CAPEC-153 Input Data Manipulation, poses a high availability impact, with a base CVSS score of 7.5.

Technical Details of CVE-2023-33217

The vulnerability affects multiple IDEMIA products, including SIGMA Lite & Lite +, SIGMA Wide, MorphoWave Compact/XP, VisionPass, and MorphoWave SP.

Vulnerability Description

Abusing the design flaw in firmware upgrades can lead to a permanent denial of service on affected IDEMIA terminals.

Affected Systems and Versions

Products like SIGMA Lite & Lite +, SIGMA Wide, MorphoWave Compact/XP, VisionPass, and MorphoWave SP are vulnerable if running versions less than specified (e.g., less than 4.15.5).

Exploitation Mechanism

The vulnerability's exploitation involves manipulating input data in the firmware upgrade mechanism.

Mitigation and Prevention

To safeguard against CVE-2023-33217, immediate actions and long-term security practices are essential.

Immediate Steps to Take

It is crucial to update affected IDEMIA terminals to versions equal to or beyond the fixed versions (e.g., 4.15.5 or higher).

Long-Term Security Practices

Enforce stringent security measures, review firmware upgrade processes, and monitor for potential denial of service attempts.

Patching and Updates

Regularly apply security updates and patches released by IDEMIA to address vulnerabilities and enhance device security.